Andreas Thomas

List of Publications by Year
in descending order

163	5,101	76196	133063
papers	citations	40 h-index	59 g-index

164	164	164	2862
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Analytical and Bioanalytical Chemistry, 2012, 403, 1279-1289.	1.9	136
2	Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Communications in Mass Spectrometry, 2006, 20, 2252-2258.	0.7	114
3	Screening for the synthetic cannabinoid JWHâ€018 and its major metabolites in human doping controls. Drug Testing and Analysis, 2011, 3, 609-620.	1.6	113
4	Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatographyâ^'Tandem Mass Spectrometry for Doping Control Purposes. Analytical Chemistry, 2005, 77, 3579-3585.	3.2	105
5	Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrometry Reviews, 2008, 27, 35-50.	2.8	98
6	Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry. Clinical Chemistry, 2014, 60, 541-548.	1.5	96
7	Confiscated black market products and nutritional supplements with nonâ€approved ingredients analyzed in the cologne doping control laboratory 2009. Drug Testing and Analysis, 2010, 2, 533-537.	1.6	92
8	Doping Control Analysis of Intact Rapid-Acting Insulin Analogues in Human Urine by Liquid Chromatographyâ^'Tandem Mass Spectrometry. Analytical Chemistry, 2006, 78, 1897-1903.	3.2	91
9	Current role of LC-MS(/MS) in doping control. Analytical and Bioanalytical Chemistry, 2011, 401, 405-420.	1.9	86
10	Immunoaffinity purification of peptide hormones prior to liquid chromatographyâ€“mass spectrometry in doping controls. Methods, 2012, 56, 230-235.	1.9	85
11	Identification of black market products and potential doping agents in Germany 2010â€“2013. European Journal of Clinical Pharmacology, 2014, 70, 1303-1311.	0.8	84
12	Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 401, 507-516.	1.9	83
13	Mass Spectrometric Identification of Degradation Products of Insulin and Its Long-Acting Analogues in Human Urine for Doping Control Purposes. Analytical Chemistry, 2007, 79, 2518-2524.	3.2	75
14	Dietary Supplement and Food Contaminations and Their Implications for Doping Controls. Foods, 2020, 9, 1012.	1.9	74
15	Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nanoâ€UPLC coupled with highâ€resolution/highâ€accuracy mass spectrometry. Drug Testing and Analysis, 2009, 1, 219-227.	1.6	72
16	Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. Analytical and Bioanalytical Chemistry, 2011, 401, 493-505.	1.9	66
17	Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 404, 1813-1822.	1.9	65
18	Mass spectrometric determination of gonadotrophinâ€releasing hormone (GnRH) in human urine for doping control purposes by means of LCâ€“ESIâ€MS/MS. Journal of Mass Spectrometry, 2008, 43, 908-915.	0.7	62

#	Article	IF	Citations
19	Analysis of Confiscated Black Market Drugs Using Chromatographic and Mass Spectrometric Approaches. Journal of Analytical Toxicology, 2008, 32, 232-240.	1.7	62
20	Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing. Drug Testing and Analysis, 2013, 5, 810-818.	1.6	62
21	Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LCâ€Mâ€MS). Drug Testing and Analysis, 2014, 6, 1125-1132.	1.6	62
22	Comprehensive plasmaâ€screening for known and unknown substances in doping controls. Rapid Communications in Mass Spectrometry, 2010, 24, 1124-1132.	0.7	60
23	Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. Analytical and Bioanalytical Chemistry, 2012, 403, 2715-2724.	1.9	58
24	Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2013, 131, 743-751.e9.	1.5	58
25	Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst, The, 2011, 136, 1003-1012.	1.7	57
26	Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. Journal of Mass Spectrometry, 2009, 44, 442-460.	0.7	56
27	Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. Journal of Chromatography A, 2012, 1259, 251-257.	1.8	54
28	Identification of the growthâ€hormoneâ€releasing peptideâ€2 (GHRPâ€2) in a nutritional supplement. Drug Testing and Analysis, 2010, 2, 144-148.	1.6	52
29	Use of dried blood spots in doping control analysis of anabolic steroid esters. Journal of Pharmaceutical and Biomedical Analysis, 2014, 96, 21-30.	1.4	51
30	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (Sâ€4) for routine doping control purposes. Rapid Communications in Mass Spectrometry, 2010, 24, 2245-2254.	0.7	48
31	â€œDilute-and-injectâ€•multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing. Analytical and Bioanalytical Chemistry, 2015, 407, 5365-5379.	1.9	48
32	Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 482-496.	1.4	48
33	Determination of Vasopressin and Desmopressin in urine by means of liquid chromatography coupled to quadrupole time-of-flight mass spectrometry for doping control purposes. Analytica Chimica Acta, 2011, 707, 107-113.	2.6	47
34	Metabolism of Growth Hormone Releasing Peptides. Analytical Chemistry, 2012, 84, 10252-10259.	3.2	47
35	Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing?. Rapid Communications in Mass Spectrometry, 2013, 27, 507-512.	0.7	46
36	Insulin. Handbook of Experimental Pharmacology, 2009, , 209-226.	0.9	45

#	Article	IF	Citations
37	Trafficking of drug candidates relevant for sports drug testing: Detection of nonâ€approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Testing and Analysis, 2011, 3, 331-336.	1.6	45
38	Application of FAIMS to anabolic androgenic steroids in sport drug testing. Drug Testing and Analysis, 2009, 1, 545-553.	1.6	44
39	Characterization of two major urinary metabolites of the PPARÎ´-agonist GW1516 and implementation of the drug in routine doping controls. Analytical and Bioanalytical Chemistry, 2010, 396, 2479-2491.	1.9	43
40	Dried blood spots (DBS) for doping control analysis. Drug Testing and Analysis, 2011, 3, 806-813.	1.6	42
41	Measuring insulin in human vitreous humour using LCâ€MS/MS. Drug Testing and Analysis, 2012, 4, 53-56.	1.6	42
42	Characterization of in vitro generated metabolites of the selective androgen receptor modulators Sâ€22 and Sâ€23 and in vivo comparison to postâ€administration canine urine specimens. Drug Testing and Analysis, 2010, 2, 589-598.	1.6	41
43	Ultrahigh pressure liquid chromatographyâ€“(tandem) mass spectrometry in human sports drug testing: Possibilities and limitations. Journal of Chromatography A, 2013, 1292, 38-50.	1.8	41
44	Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LCâ€“MS/MS. Analytical and Bioanalytical Chemistry, 2008, 391, 251-261.	1.9	40
45	Identification of Human Pituitary Growth Hormone Variants by Mass Spectrometry. Journal of Proteome Research, 2009, 8, 1071-1076.	1.8	40
46	Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. Journal of Separation Science, 2016, 39, 333-341.	1.3	40
47	Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS. Analytical and Bioanalytical Chemistry, 2020, 412, 3765-3777.	1.9	40
48	Detection of Surreptitious Administration of Analog Insulin to an 8-Week-Old Infant. Pediatrics, 2010, 125, e1236-e1240.	1.0	39
49	Doping control analysis of selected peptide hormones using LCâ€“MS(/MS). Forensic Science International, 2011, 213, 35-41.	1.3	39
50	Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2016, 123, 132-140.	1.4	39
51	Analytical Approaches in Human Sports Drug Testing: Recent Advances, Challenges, and Solutions. Analytical Chemistry, 2020, 92, 506-523.	3.2	39
52	Determination of Synacthen in urine for sports drug testing by means of nanoâ€ultraâ€performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2009, 23, 2669-2674.	0.7	38
53	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator Sâ€22 to identify potential targets for routine doping controls. Rapid Communications in Mass Spectrometry, 2011, 25, 2187-2195.	0.7	38
54	Traditional Chinese medicine and sports drug testing: identification of natural steroid administration in doping control urine samples resulting from musk (pod) extracts. British Journal of Sports Medicine, 2013, 47, 109-114.	3.1	37

#	Article	IF	Citations
55	Can dried blood spots (DBS) contribute to conducting comprehensive SARSâ€CoVâ€2 antibody tests?. Drug Testing and Analysis, 2020, 12, 994-997.	1.6	37
56	Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horseâ€racing. Rapid Communications in Mass Spectrometry, 2008, 22, 355-362.	0.7	36
57	Doping control analysis of tricyclic tetrahydroquinolineâ€derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 2471-2478.	0.7	36
58	Combination of carbon isotope ratio with hydrogen isotope ratio determinations in sports drug testing. Analytical and Bioanalytical Chemistry, 2013, 405, 5455-5466.	1.9	36
59	Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRPâ€1, GHRPâ€2, GHRPâ€6, Hexarelin, and Ipamorelin. Drug Testing and Analysis, 2015, 7, 919-925.	1.6	35
60	Doping control analysis of emerging drugs in human plasma â€“ identification of GW501516, Sâ€107, JTVâ€519, and Sâ€40503. Rapid Communications in Mass Spectrometry, 2009, 23, 1139-1146.	0.7	34
61	Quantification of urinary AICAR concentrations as a matter of doping controls. Analytical and Bioanalytical Chemistry, 2010, 396, 2899-2908.	1.9	34
62	Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Hormone and IGF Research, 2010, 20, 386-390.	0.5	33
63	Synthesis, characterisation, and mass spectrometric detection of a pegylated EPOâ€mimetic peptide for sports drug testing purposes. Rapid Communications in Mass Spectrometry, 2011, 25, 2115-2123.	0.7	33
64	Characterization of a nonâ€approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phaseâ€I metabolites for human sports drug testing. Rapid Communications in Mass Spectrometry, 2015, 29, 991-999.	0.7	33
65	Expanded test method for peptides >2 kDa employing immunoaffinity purification and LCâ€HRMS/MS. Drug Testing and Analysis, 2015, 7, 990-998.	1.6	33
66	Do dried blood spots (DBS) have the potential to support result management processes in routine sports drug testing?. Drug Testing and Analysis, 2020, 12, 704-710.	1.6	33
67	Investigations on hydrogen isotope ratios of endogenous urinary steroids: referenceâ€populationâ€based thresholds and proofâ€ofâ€concept. Drug Testing and Analysis, 2012, 4, 717-727.	1.6	32
68	Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatographyâ€“high resolution mass spectrometry. Drug Testing and Analysis, 2018, 10, 1761-1768.	1.6	31
69	Dietary Ï‰3-and Ï‰6-Polyunsaturated fatty acids reconstitute fertility of Juvenile and adult Fads2-Deficient mice. Molecular Metabolism, 2020, 36, 100974.	3.0	31
70	Quantification of intact human insulinâ€like growth factorâ€I in serum by nanoâ€ultrahighâ€performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2014, 28, 1426-1432.	0.7	30
71	Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and Bioanalytical Chemistry, 2016, 408, 3145-3153.	1.9	30
72	Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). Forensic Science International, 2019, 303, 109925.	1.3	30

#	Article	IF	Citations
73	Post-mortem vitreous humour as potential specimen for detection of insulin analogues by LCâ€“MS/MS. Forensic Science International, 2013, 233, 328-332.	1.3	26
74	Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics, 2014, 11, 663-673.	1.3	26
75	Simplified quantification of insulin, its synthetic analogs and Câ€peptide in human plasma by means of LCâ€HRMS. Drug Testing and Analysis, 2020, 12, 382-390.	1.6	26
76	Rapid screening of polysaccharideâ€based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatographyâ€“tandem mass spectrometry. Biomedical Chromatography, 2008, 22, 695-701.	0.8	25
77	Measuring xenon in human plasma and blood by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2014, 28, 1501-1506.	0.7	25
78	Proteolysis and autolysis of proteases and the detection of degradation products in doping control. Drug Testing and Analysis, 2009, 1, 81-86.	1.6	24
79	Effects of endurance exercise on the urinary proteome analyzed by 2â€D PAGE and Orbitrap MS. Proteomics - Clinical Applications, 2010, 4, 568-576.	0.8	24
80	Determination of SynacthenÂ® in dried blood spots for doping control analysis using liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2015, 407, 4709-4720.	1.9	24
81	Testing for the erythropoiesisâ€stimulating agent Sotatercept/ACEâ€011 (ActRIIAâ€Fc) in serum by means of Western blotting and LCâ€HRMS. Drug Testing and Analysis, 2016, 8, 1152-1161.	1.6	24
82	Structure Elucidation of the Diagnostic Product Ion at m/z 97 Derived from Androst-4-en-3-One-Based Steroids by ESI-CID and IRMPD Spectroscopy. Journal of the American Society for Mass Spectrometry, 2012, 23, 537-546.	1.2	23
83	Metabolism of human insulin after subcutaneous administration: A possible means to uncover insulin misuse. Analytica Chimica Acta, 2015, 897, 53-61.	2.6	23
84	Dried blood spots (DBS) in doping controls: a complementary matrix for improved in- and out-of-competition sports drug testing strategies. Analytical Methods, 2015, 7, 7596-7605.	1.3	23
85	Mass spectrometric detection of siRNA in plasma samples for doping control purposes. Analytical and Bioanalytical Chemistry, 2010, 398, 1305-1312.	1.9	22
86	Determination of ¹³C/¹²C ratios of endogenous urinary 5â€aminoâ€imidazoleâ€4â€carboxamide 1Î²â€Dâ€ribofuranoside (AICAR). Rapid Communications in Mass Spectrometry, 2014, 28, 1194-1202.	0.7	22
87	Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (<) Tj ETQq1 1 0.784314 rgBT /Overloc 2018, 10, 1755-1760.	1.6	22
88	Recent advances in the determination of insulins from biological fluids. Advances in Clinical Chemistry, 2019, 93, 115-167.	1.8	22
89	Determination of Selected Stimulants in Urine for Sports Drug Analysis by Solid Phase Extraction via Cation Exchange and Means of Liquid Chromatography-Tandem Mass Spectrometry. European Journal of Mass Spectrometry, 2008, 14, 135-143.	0.5	21
90	Comparison of the urinary protein patterns of athletes by 2Dâ€gel electrophoresis and mass spectrometryâ€”a pilot study. Drug Testing and Analysis, 2009, 1, 382-386.	1.6	21

#	Article	IF	Citations
91	Targeting prohibited substances in doping control blood samples by means of chromatographicâ€“mass spectrometric methods. Analytical and Bioanalytical Chemistry, 2013, 405, 9655-9667.	1.9	20
92	Simultaneous determination of insulin, DesB30 insulin, proinsulin, and C-peptide in human plasma samples by liquid chromatography coupled to high resolution mass spectrometry. Forensic Toxicology, 2017, 35, 106-113.	1.4	20
93	Immunoaffinity techniques coupled to mass spectrometry for the analysis of human peptide hormones: advances and applications. Expert Review of Proteomics, 2017, 14, 799-807.	1.3	20
94	Validated hemoglobinâ€depletion approach for red blood cell lysate proteome analysis by means of 2<scp>D PAGE</scp> and <scp>O</scp>rbitrap <scp>MS</scp>. Electrophoresis, 2012, 33, 2537-2545.	1.3	19
95	Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS. Analytical and Bioanalytical Chemistry, 2013, 405, 9703-9709.	1.9	19
96	Do dried blood spots have the potential to support result management processes in routine sports drug testing?â€”Part 2: Proactive sampling for followâ€up investigations concerning atypical or adverse analytical findings. Drug Testing and Analysis, 2021, 13, 505-509.	1.6	19
97	Storageâ€induced changes of the cytosolic red blood cell proteome analyzed by 2D DIGE and highâ€resolution/highâ€accuracy MS. Proteomics, 2012, 12, 3263-3272.	1.3	17
98	Detection of small interfering RNA (siRNA) by mass spectrometry procedures in doping controls. Drug Testing and Analysis, 2013, 5, 853-860.	1.6	17
99	Isolation, Enrichment, and Analysis of Erythropoietins in Anti-Doping Analysis by Receptor-Coated Magnetic Beads and Liquid Chromatographyâ€“Mass Spectrometry. Analytical Chemistry, 2014, 86, 12014-12021.	3.2	17
100	Complementing the characterization of in vivo generated Nâ€glucuronic acid conjugates of stanozolol by collision cross section computation and analysis. Drug Testing and Analysis, 2015, 7, 1050-1056.	1.6	17
101	Organ distribution of 4-MEC, MDPV, methoxetamine and Î±-PVP: comparison of QuEChERS and SPE. Forensic Toxicology, 2018, 36, 320-333.	1.4	17
102	Inter-Laboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured Intact by Mass Spectrometry. Clinical Chemistry, 2020, 66, 579-586.	1.5	17
103	First use of the antiâ€VWF nanobody caplacizumab to treat iTTP in pregnancy. British Journal of Haematology, 2022, 196, .	1.2	17
104	Identification of fibroblast growth factor 1 (FGFâ€1) in a black market product. Drug Testing and Analysis, 2011, 3, 791-797.	1.6	16
105	Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches. Drug Testing and Analysis, 2014, 6, 1197-1205.	1.6	16
106	Liquid Chromatography-High Resolution/High Accuracy (Tandem) Mass Spectrometry-Based Identification of in vivo Generated Metabolites of the Selective Androgen Receptor Modulator ACP-105 for Doping Control Purposes. European Journal of Mass Spectrometry, 2014, 20, 73-83.	0.5	16
107	Development of two complementary LCâ€“HRMS methods for analyzing sotatercept in dried blood spots for doping controls. Bioanalysis, 2019, 11, 923-940.	0.6	16
108	Development of a mass spectrometry based detection method for the mitochondrionâ€derived peptide MOTSâ€c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry, 2019, 33, 371-380.	0.7	16

#	Article	IF	Citations
109	Screening for the calstabinâ€ryanodine receptor complex stabilizers JTVâ€519 and Sâ€107 in doping control analysis. Drug Testing and Analysis, 2009, 1, 32-42.	1.6	15
110	Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. Growth Hormone and IGF Research, 2014, 24, 276-280.	0.5	15
111	Characterization of in vitro generated metabolites of selected peptides <2ÂkDa prohibited in sports. Drug Testing and Analysis, 2017, 9, 1799-1803.	1.6	15
112	In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and Cunninghamella elegans and their detection in urine samples. Analytical and Bioanalytical Chemistry, 2019, 411, 3561-3579.	1.9	15
113	Recent advances in identifying and utilizing metabolites of selected doping agents in human sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114312.	1.4	15
114	Mass spectrometric detection of peginesatide in human urine in doping control analysis. Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 512-517.	1.4	14
115	Combined detection of the ActRIIâ€Fc fusion proteins Sotatercept (ActRIIAâ€Fc) and Luspatercept (modified) Tj ETQq1 1 0.784314 rgB Testing and Analysis, 2018, 10, 1714-1721.	1.6	14
116	Characterization of InÂVitro Synthesized Equine Metabolites of the Selective Androgen Receptor Modulators S24 and S4. Journal of Equine Veterinary Science, 2012, 32, 562-568.	0.4	13
117	Detection of an unknown fusion protein in confiscated black market products. Drug Testing and Analysis, 2014, 6, 1117-1124.	1.6	13
118	Identification and characterization of in vitro and in vivo generated metabolites of the adiponectin receptor agonists AdipoRon and 112254. Journal of Pharmaceutical and Biomedical Analysis, 2016, 125, 68-76.	1.4	13
119	First Steps toward Uncovering Gene Doping with CRISPR/Cas by Identifying SpCas9 in Plasma via HPLCâ€“HRMS/MS. Analytical Chemistry, 2020, 92, 16322-16328.	3.2	13
120	Detection of the protease Bacillolysin in dopingâ€control urine samples. Drug Testing and Analysis, 2009, 1, 143-145.	1.6	12
121	Mass Spectrometry-Based Characterization of New Drugs and Methods of Performance Manipulation in Doping Control Analysis. European Journal of Mass Spectrometry, 2010, 16, 301-312.	0.5	12
122	Identification of Selected in vitro-Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control Purposes. European Journal of Mass Spectrometry, 2016, 22, 49-59.	0.5	12
123	Determination of LongR 3 -IGF-I, R 3 -IGF-I, Des1-3 IGF-I and their metabolites in human plasma samples by means of LC-MS. Growth Hormone and IGF Research, 2017, 35, 33-39.	0.5	12
124	Analytical challenges in sports drug testing. Analytical and Bioanalytical Chemistry, 2018, 410, 2275-2281.	1.9	12
125	Detection of the Human Antiâ€ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LCâ€HRMS. Proteomics - Clinical Applications, 2018, 12, e1700120.	0.8	12
126	Facilitated Qualitative Determination of Insulin, Its Synthetic Analogs, and C-Peptide in Human Urine by Means of LCâ€“HRMS. Metabolites, 2021, 11, 309.	1.3	12

#	Article	IF	Citations
127	Screening for benfluorex and its major urinary metabolites in routine doping controls. Analytical and Bioanalytical Chemistry, 2011, 401, 543-551.	1.9	11
128	Analysis of octopamine in human doping control samples. Biomedical Chromatography, 2012, 26, 610-615.	0.8	11
129	Analysis of new growth promoting black market products. Growth Hormone and IGF Research, 2018, 41, 1-6.	0.5	11
130	Detection of the myostatinâ€neutralizing antibody Domagrozumab in serum by means of Western blotting and LCâ€HRMS. Drug Testing and Analysis, 2019, 11, 1714-1723.	1.6	11
131	Electron ionization mass spectrometry of the ryanodine receptor-based Ca2+ -channel stabilizer S-107 and its implementation into routine doping control. Rapid Communications in Mass Spectrometry, 2009, 23, 2363-2370.	0.7	10
132	Formation of the diuretic chlorazanil from the antimalarial drug proguanilâ€"Implications for sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 208-213.	1.4	10
133	Myostatin inhibitors in sports drug testing: Detection of myostatinâ€neutralizing antibodies in plasma/serum by affinity purification and Western blotting. Proteomics - Clinical Applications, 2016, 10, 195-205.	0.8	10
134	Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. International Journal of Legal Medicine, 2018, 132, 1645-1657.	1.2	10
135	Probing for the presence of doping agents in exhaled breath using chromatographic/mass spectrometric approaches. Rapid Communications in Mass Spectrometry, 2021, 35, e8939.	0.7	9
136	Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 649-659.	1.8	9
137	Doping Control Analysis of Metamfepramone and Two Major Metabolites Using Liquid Chromatography-Tandem Mass Spectrometry. European Journal of Mass Spectrometry, 2009, 15, 507-515.	0.5	8
138	Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. International Journal of Legal Medicine, 2019, 133, 1049-1064.	1.2	8
139	Identification of metabolites of peptide-derived drugs using an isotope-labeled reporter ion screening strategy. Clinical Chemistry and Laboratory Medicine, 2020, 58, 690-700.	1.4	8
140	Detection of follistatinâ€based inhibitors of the TGFâ€Î²2 signaling pathways in serum/plasma by means of LCâ€HRMS/MS and Western blotting. Drug Testing and Analysis, 2020, 12, 1636-1648.	1.6	8
141	Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches. Analytica Chimica Acta, 2022, 1202, 339661.	2.6	7
142	Probing for the presence of semenogelin in human urine by immunological and chromatographicâ€mass spectrometric methods in the context of sports drug testing. Analytical Science Advances, 2022, 3, 21-28.	1.2	7
143	Detection of Peginesatide in Equine Serum Using Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. European Journal of Mass Spectrometry, 2012, 18, 407-412.	0.5	6
144	Isotopeâ€dilution mass spectrometric quantification of the prodrug lisdexamfetamine in human urine in doping control analysis. Rapid Communications in Mass Spectrometry, 2014, 28, 781-786.	0.7	6

#	Article	IF	Citations
145	EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS. Journal of the American Society for Mass Spectrometry, 2015, 26, 1617-1625.	1.2	6
146	In vitro elucidation of the metabolic profile of the synthetic cannabinoid receptor agonists JWH-175 and JWH-176. Forensic Toxicology, 2016, 34, 353-362.	1.4	6
147	Depletion of clomiphene residues in eggs and muscle after oral administration to laying hens. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2021, 38, 1875-1882.	1.1	6
148	Factitious administration of analogue insulin to a 2-year-old child. British Journal of Diabetes, 2016, 16, 82.	0.1	6
149	Effects of gamma irradiation and 15 days of subsequent ex vivo storage on the cytosolic red blood cell proteome analyzed by 2Dâ€ÐIGE and Orbitrap MS. Proteomics - Clinical Applications, 2013, 7, 561-570.	0.8	5
150	Peptidic drugs and drug candidates in sports drug testing: agents affecting mitochondrial biogenesis or preventing activin receptor II activation. Current Opinion in Endocrine and Metabolic Research, 2019, 9, 22-27.	0.6	5
151	Novel CB1-ligands maintain homeostasis of the endocannabinoid system in Ï‰3- and Ï‰6-long-chain-PUFA deficiency. Journal of Lipid Research, 2019, 60, 1396-1409.	2.0	5
152	Comprehensive insights into the formation of metabolites of the ghrelin mimetics capromorelin, macimorelin and tabimorelin as potential markers for doping control purposes. Biomedical Chromatography, 2021, 35, e5075.	0.8	5
153	Effects of different exercise intensities in the morning on football performance components in the afternoon. German Journal of Exercise and Sport Research, 2018, 48, 235-244.	1.0	4
154	Mass spectrometric identification and characterization of urinary metabolites of isopropylnorsynephrine for doping control purposes. Analytical Science Advances, 2021, 2, 334-341.	1.2	4
155	Urinary phenylethylamine metabolites as potential markers for sports drug testing purposes. Biomedical Chromatography, 2022, 36, e5274.	0.8	4
156	Probing for factors influencing exhaled breath drug testing in sportsâ€" Pilot studies focusing on the tested individual's tobacco smoking habit and sex. Rapid Communications in Mass Spectrometry, 2022, 36, e9262.	0.7	4
157	Stereoisomers in sports drug testing: Analytical strategies and applications. Journal of Chromatography A, 2022, 1674, 463154.	1.8	4
158	Influence of repeated subcutaneous Gâ€CSF injections on selected blood parameters relevant for monitoring programmes in sports drug testing. Drug Testing and Analysis, 2012, 4, 798-802.	1.6	3
159	Determination of ghrelin and desacyl ghrelin in human plasma and urine by means of LCâ€"MS/MS for doping controls. Drug Testing and Analysis, 2021, , .	1.6	3
160	Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry. Metabolites, 2022, 12, 146.	1.3	3
161	Phase I-metabolism studies of the synthetic cannabinoids PX-1 and PX-2 using three different in vitro models. Forensic Toxicology, 2022, 40, 244-262.	1.4	3
162	Effect of changes in the deuterium content of drinking water on the hydrogen isotope ratio of urinary steroids in the context of sports drug testing. Analytical and Bioanalytical Chemistry, 2013, 405, 2911-2921.	1.9	2

#	Article	IF	Citations
163	Analytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 2016, 408, 6431-6442.	1.9	2